Co-Inventors
Seder, Robert
Seymour, Leonard
Therapeutic Areas
Rare/Neglected Diseases
Infectious Disease
Immunology
The "Adjuvant pro-drug platform for gene delivery and spatiotemporal control over immune activation" is a groundbreaking technology that addresses the limitations of DNA and RNA-based vaccines by providing spatiotemporal control over immune activation. This platform utilizes a cationic polymer with pro-drug Toll-like receptor-7/8 agonists attached, allowing for the complexation of RNA and DNA to form nanoparticles for in vivo administration. The pro-drug TLR-7/8 agonists have enzyme-degradable bonds with slow release rates, enabling the delay of immune activation for up to 8 days. This precise control ensures optimal innate immune stimulation without compromising transgene expression, making it a promising approach for enhancing the efficacy of DNA and RNA-based vaccines for infectious diseases and cancer immunotherapy.
Commercial Applications
The adjuvant pro-drug platform has diverse potential applications in the fields of infectious diseases and cancer immunotherapy. For infectious diseases, this technology could enable the rapid development and deployment of highly immunogenic DNA-based vaccines against emerging pathogens. Its ability to enhance immune responses without compromising transgene expression is particularly valuable in the context of rapidly evolving pathogens where quick and effective vaccination is critical. In cancer immunotherapy, the platform could be used to deliver personalized neoantigens, offering a tailored approach to treatment that targets specific cancer mutations. This technology has the potential to revolutionize vaccine development and immunotherapy by providing a versatile platform for enhancing immune responses against a variety of diseases.
Competitive Advantages
The adjuvant pro-drug platform offers several competitive advantages over existing technologies. Its ability to provide spatiotemporal control over immune activation sets it apart from traditional adjuvants, which often activate immune responses indiscriminately and can lead to reduced transgene expression. By delaying immune activation until after adequate gene expression has occurred, this platform maximizes the effectiveness of DNA and RNA-based vaccines. Additionally, the platform's versatility allows for the delivery of a wide range of antigens, making it applicable to various infectious diseases and cancer types. Its potential to significantly enhance the immunogenicity of vaccines while maintaining high levels of transgene expression positions it as a leading candidate for improving vaccine efficacy and personalized medicine approaches.
